Free Trial

Walgreens Boots Alliance (WBA) Stock Price, News & Analysis

$15.54
-0.39 (-2.45%)
(As of 06/12/2024 ET)
Today's Range
$15.49
$16.24
50-Day Range
$14.89
$19.18
52-Week Range
$14.62
$32.89
Volume
9.28 million shs
Average Volume
13.11 million shs
Market Capitalization
$13.41 billion
P/E Ratio
N/A
Dividend Yield
6.44%
Price Target
$23.57

Walgreens Boots Alliance MarketRank™ Stock Analysis

Analyst Rating
Reduce
1.88 Rating Score
Upside/​Downside
51.7% Upside
$23.57 Price Target
Short Interest
Healthy
5.97% of Float Sold Short
Dividend Strength
Moderate
Based on Four Factors
Sustainability
-2.09
Upright™ Environmental Score
News Sentiment
0.59mentions of Walgreens Boots Alliance in the last 14 days
Based on 19 Articles This Week
Insider Trading
Acquiring Shares
$170,430 Bought Last Quarter
Proj. Earnings Growth
-4.36%
From $3.21 to $3.07 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.76 out of 5 stars

Retail/Wholesale Sector

14th out of 195 stocks

Drug Stores & Proprietary Stores Industry

2nd out of 3 stocks

WBA stock logo

About Walgreens Boots Alliance Stock (NASDAQ:WBA)

Walgreens Boots Alliance Inc. is a world-renowned healthcare, pharmacy, and retailing company. Founded in 1901 by John Boot and Charles R. Walgreen, the company has grown to become a leader in the industry, operating in nine countries and providing access to healthcare services to millions of people around the world. Walgreens Boots Alliance operates through three main segments: U.S. Retail Pharmacy, International, and U.S. Healthcare.

The U.S. Retail Pharmacy segment includes the Walgreens business, which operates health and wellness services, retail drugstores, specialty and home delivery pharmacy services, and an equity method investment in AmerisourceBergen. Walgreens stores have locations in all 50 U.S. states, the District of Columbia, Puerto Rico, and the U.S. Virgin Islands, offering access to consumer goods and services, pharmacy, photo department, and health and wellness services. Walgreens also operates online stores like Walgreens.com, Drugstore.com, VisionDirect.com, and Beauty.com.

The International segment consists of pharmacy-led health and beauty retail businesses outside the United States and a pharmaceutical wholesaling and distribution company in Germany. This segment includes the Boots brand, which has a history stretching back over 170 years in the United Kingdom, and stores in Ireland and Thailand with Boots franchise operations in the Middle East and Indonesia. The remainder of the division comprises Farmacias Ahumada (FASA) pharmacies in Chile and Benavides in Mexico. The Pharmaceutical Wholesale Division, including the Alliance Healthcare brand, supplied medicines and other healthcare products to more than 115,000  doctors, health centers,  pharmacies, and hospitals annually in eleven countries through 306 distribution centers. AmerisourceBergen purchased most of the Alliance Healthcare wholesale division in June 2021 for $6.275bn in cash.

The U.S. Healthcare segment is a consumer-centric, technology-enabled healthcare business that engages consumers through a personalized, omnichannel experience across the care journey. This segment includes the operation of 334 VillageMD clinics, including 146 co-located clinics, 124 standalone clinics, and 64 affiliate clinics.

Walgreens Boots Alliance produces many brands, including Soltan and Botanics, Boots Pharmaceuticals, and Boots Laboratories, No. 7, that Alliance Boots and Walgreens sought to launch internationally following the first share purchase in 2012. These brands include the famous No. 7 beauty serums, developed in Nottingham, the UVA 5-star suncare protection by Soltan, and the Botanics range, developed in partnership with the Royal Botanic Gardens, Kew. Boots' brand range includes medicines, healthcare products, skincare, and many more. Walgreens also has a self-branded line of products called "Well at Walgreens."

For the fiscal year 2020, Walgreens Boots Alliance reported earnings of US$456 million. The reported revenue was US$139.5 billion, an increase of 2.5% over the previous fiscal cycle. As of 2022, Walgreens Boots Alliance is ranked #18 on the Fortune 500 rankings. The company pays a Quarterly dividend of $0.48, representing an annual dividend yield of 5.08%. Wall Street analysts consider Walgreens stock to be Undervalued. 

Walgreens Boots Alliance has 862,503,540 shares outstanding, and its market cap is currently $31.99B. The company’s EPS estimate is $1.12, and its most recent earnings report saw it beat expectations with an EPS of $1.16. Following the earnings report, the stock price went down -6.135%. Among the most significant hedge funds holding Walgreens Boots Alliance’s shares is Antipodes Partners Ltd., which owns shares valued at $58M.

Walgreens Boots Alliance is a global healthcare leader committed to providing high-quality services and products to its customers. The company’s innovative strategies have earned it a reputation as a reliable and reputable partner for healthcare providers and consumers. With its wide array of products and services, Walgreens Boots Alliance is well-positioned to continue growing and meeting the needs of its customers for years to come.

WBA Stock Price History

WBA Stock News Headlines

Top 3 Bargain Stocks to Watch Near Their 52-Week Low Prices
Three stocks come to give investors a chance to beat stagflation, analysts think all of these could rise by double-digits in the coming months.
Need a pharmacy? These states and neighborhoods have less access
Urban and rural communities have come to depend on pharmacies as a trusted care option and a place for advice
Red Nose Day 2024 fights child poverty with the 'whimsy' of a candy castle, monster truck and Legos
Red Nose Day has raised $370 million since 2015 to fund anti-poverty efforts
CVS Health Stock Has a Silver Lining Called Value (WBA)
As integrated healthcare retailer and insurer CVS Health prioritizes profits, it presents investors with a value not seen in years
The Next Drug You Take May be Designed By A.I.
Three stocks could give investors a better way to tap into A.I.'s future potential inside drug development, an industry that is set to grow at 29.6% until 2030
3 High-Yield Bond ETFs for Income Investors
Walgreens Down Over 3% - What's Going On?
Walgreens Introduces Summer of Savings
See More Headlines
Receive WBA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Walgreens Boots Alliance and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/28/2024
Ex-Dividend for 6/12 Dividend
5/20/2024
Today
6/12/2024
Dividend Payable
6/12/2024
Next Earnings (Confirmed)
6/27/2024
Fiscal Year End
8/31/2024

Industry, Sector and Symbol

Industry
Drug stores & proprietary stores
Sub-Industry
Drug Retail
Current Symbol
NASDAQ:WBA
CUSIP
93142210
Employees
331,000
Year Founded
2014

Price Target and Rating

Average Stock Price Target
$23.57
High Stock Price Target
$35.00
Low Stock Price Target
$13.00
Potential Upside/Downside
+51.7%
Consensus Rating
Reduce
Rating Score (0-4)
1.88
Research Coverage
16 Analysts

Profitability

Net Income
$-3,080,000,000.00
Pretax Margin
-9.84%

Debt

Sales & Book Value

Annual Sales
$139.08 billion
Cash Flow
$6.42 per share
Book Value
$32.78 per share

Miscellaneous

Free Float
712,601,000
Market Cap
$13.41 billion
Optionable
Optionable
Beta
0.78

Social Links

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. Stefano Pessina (Age 83)
    Executive Chairman of the Board
    Comp: $66.73k
  • Mr. Manmohan Mahajan (Age 44)
    Executive VP & Global CFO
    Comp: $1.16M
  • Ms. Ornella BarraMs. Ornella Barra (Age 71)
    Executive VP & COO of International
    Comp: $1.44M
  • Mr. Timothy C. WentworthMr. Timothy C. Wentworth (Age 64)
    CEO & Director
  • Mr. Todd D. Heckman (Age 50)
    Senior VP, Global Controller & Chief Accounting Officer
  • Dr. Neal Joseph Sample Ph.D. (Age 49)
    Executive VP & Chief Information Officer
  • Ms. Tiffany Ann Kanaga
    Vice President of Global Investor Relations
  • Mr. Matthew D'Ambrosio (Age 54)
    Senior VP and Global Chief Compliance & Ethics Officer
  • Ms. Lanesha T. Minnix (Age 49)
    Executive VP & Global Chief Legal Officer
  • Ms. Elizabeth L. Burger (Age 53)
    Executive VP & Chief Human Resources Officer

Should I Buy Walgreens Boots Alliance Stock? WBA Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Walgreens Boots Alliance, Inc.:

  • Walgreens Boots Alliance recently reported a positive return on equity of 12.11%, indicating efficient use of shareholder funds to generate profits.
  • Director Inderpal S. Bhandari purchased 3,000 shares of the company's stock, showing confidence in the company's future performance.
  • The company's quarterly earnings results exceeded analysts' expectations, with an EPS of $1.20, showcasing strong financial performance.
  • Walgreens Boots Alliance pays a quarterly dividend with an annualized dividend of $1.00 and a yield of 5.45%, providing potential income for investors.
  • The stock price of Walgreens Boots Alliance has shown resilience, with a 1-year low of $17.12 and a 1-year high of $32.89, offering potential for capital appreciation.

Cons

Investors should be bearish about investing in Walgreens Boots Alliance, Inc. for these reasons:

  • Analysts have issued mixed ratings on the company, with some setting price targets below the current stock price, indicating potential downside risk.
  • Walgreens Boots Alliance has a debt-to-equity ratio of 0.50, which may raise concerns about the company's financial leverage and ability to manage debt.
  • The company's quick ratio of 0.32 and current ratio of 0.66 suggest potential liquidity challenges in meeting short-term obligations.
  • Insiders own 17.40% of the company's stock, which could lead to conflicts of interest or lack of alignment with external shareholders.
  • Despite recent positive financial results, the company's net margin remains negative at -4.18%, indicating ongoing profitability challenges.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, June 4, 2024. Please send any questions or comments about these Walgreens Boots Alliance pros and cons to contact@marketbeat.com.

WBA Stock Analysis - Frequently Asked Questions

Should I buy or sell Walgreens Boots Alliance stock right now?

16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Walgreens Boots Alliance in the last year. There are currently 4 sell ratings, 10 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" WBA shares.
View WBA analyst ratings
or view top-rated stocks.

What is Walgreens Boots Alliance's stock price target for 2024?

16 brokers have issued 12-month price targets for Walgreens Boots Alliance's shares. Their WBA share price targets range from $13.00 to $35.00. On average, they anticipate the company's share price to reach $23.57 in the next twelve months. This suggests a possible upside of 51.7% from the stock's current price.
View analysts price targets for WBA
or view top-rated stocks among Wall Street analysts.

How have WBA shares performed in 2024?

Walgreens Boots Alliance's stock was trading at $26.11 at the start of the year. Since then, WBA stock has decreased by 40.5% and is now trading at $15.54.
View the best growth stocks for 2024 here
.

When is Walgreens Boots Alliance's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, June 27th 2024.
View our WBA earnings forecast
.

How can I listen to Walgreens Boots Alliance's earnings call?

Walgreens Boots Alliance will be holding an earnings conference call on Thursday, June 27th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Walgreens Boots Alliance's earnings last quarter?

Walgreens Boots Alliance, Inc. (NASDAQ:WBA) posted its quarterly earnings results on Thursday, March, 28th. The pharmacy operator reported $1.20 EPS for the quarter, beating the consensus estimate of $0.82 by $0.38. The pharmacy operator had revenue of $37.05 billion for the quarter, compared to the consensus estimate of $35.86 billion. Walgreens Boots Alliance had a negative net margin of 4.18% and a positive trailing twelve-month return on equity of 12.11%. The business's revenue for the quarter was up 6.3% on a year-over-year basis. During the same period in the previous year, the firm earned $1.16 earnings per share.
Read the conference call transcript
.

How often does Walgreens Boots Alliance pay dividends? What is the dividend yield for Walgreens Boots Alliance?

Walgreens Boots Alliance declared a quarterly dividend on Thursday, April 25th. Shareholders of record on Tuesday, May 21st will be paid a dividend of $0.25 per share on Wednesday, June 12th. This represents a $1.00 dividend on an annualized basis and a dividend yield of 6.44%. The ex-dividend date of this dividend is Monday, May 20th.
Read our dividend analysis for WBA
.

Is Walgreens Boots Alliance a good dividend stock?

Walgreens Boots Alliance (NASDAQ:WBA) pays an annual dividend of $1.00 per share and currently has a dividend yield of 6.27%. WBA has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer.
Read our dividend analysis for WBA.

What guidance has Walgreens Boots Alliance issued on next quarter's earnings?

Walgreens Boots Alliance issued an update on its FY 2024 earnings guidance on Thursday, March, 28th. The company provided EPS guidance of 3.200-3.350 for the period, compared to the consensus EPS estimate of 3.240. The company issued revenue guidance of -.

What is Stefano Pessina's approval rating as Walgreens Boots Alliance's CEO?

4,267 employees have rated Walgreens Boots Alliance Chief Executive Officer Stefano Pessina on Glassdoor.com. Stefano Pessina has an approval rating of 32% among the company's employees. This puts Stefano Pessina in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Walgreens Boots Alliance own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Walgreens Boots Alliance investors own include AT&T (T), Intel (INTC), CVS Health (CVS), Johnson & Johnson (JNJ), Walt Disney (DIS), Cisco Systems (CSCO), AbbVie (ABBV), Verizon Communications (VZ), Pfizer (PFE) and Exxon Mobil (XOM).

Who are Walgreens Boots Alliance's major shareholders?

Walgreens Boots Alliance's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (9.54%), Capital World Investors (3.37%), LSV Asset Management (0.47%), Sumitomo Mitsui Trust Holdings Inc. (0.30%), Swiss National Bank (0.25%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Inderpal S Bhandari, John Patrick Driscoll, Kevin M Ban, Manmohan Mahajan, Nancy M Schlichting, Nancy M Schlichting, Richard P Gates, Rosalind G Brewer, Timothy C Wentworth, Valerie B Jarrett and Walgreens Boots Alliance, Inc.
View institutional ownership trends
.

How do I buy shares of Walgreens Boots Alliance?

Shares of WBA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Walgreens Boots Alliance have any subsidiaries?
The following companies are subsidiares of Walgreens Boots Alliance: Alliance Boots Holdings Limited, Alliance Healthcare Deutschland AG, Bond Drug Company of Illinois LLC, Boots Opticians Professional Services Limited, Boots Properties Limited, Boots Property Partnerships, Boots Retail (Ireland) Limited, Boots Retail (Thailand) Limited, Boots UK Limited, Duane Reade, Farmacias Benavides S.A.B. de C.V., Innovation Associates Inc, Liz Earle Beauty, Prime Therapeutics Specialty Pharmacy LLC, Shields Health Solutions, Sinopharm Holding GuoDa Drug Store Co., Superior Acquisitions Limited, Superior Holdings Limited, Superior Luxco 1 S.à r.l., Take Care Health Employer Solutions, The Boots Company PLC, WBA Acquisitions UK Holdco 7 Limited, WBA Acquisitions UK Topco Limited, WBA Financial LLC, WBA International Limited, WBA Investments Inc., WBA Luxembourg 6 S.à r.l., WBA Luxembourg 7 S.à.r.l., WBAD Holdings Limited, Walgreen Arizona Drug Co., Walgreen Co., Walgreen Eastern Co. Inc., Walgreen International S.à r.l., Walgreen Investments Luxembourg S.à r.l., Walgreen Louisiana Co. Inc., Walgreen of Puerto Rico Inc., Walgreens Boots Alliance (Hong Kong) Investments Limited, Walgreens Boots Alliance Holdings LLC, Walgreens Boots Alliance Limited, Walgreens Specialty Pharmacy LLC, and Waltrust Properties Inc..
Read More
This page (NASDAQ:WBA) was last updated on 6/13/2024 by MarketBeat.com Staff

From Our Partners